首页> 外文期刊>Antiviral Research >Current status and challenges of antiretroviral research and therapy.
【24h】

Current status and challenges of antiretroviral research and therapy.

机译:抗逆转录病毒研究和治疗的现状与挑战。

获取原文
获取原文并翻译 | 示例
       

摘要

Twenty-five years after the discovery of the therapeutic activity of azidothymidine (AZT), the first antiretroviral drug used in the clinic, infection with the human immunodeficiency virus (HIV) has become, at least in the industrialized world, a manageable chronic disease with a significant improvement in life expectancy and quality. Nevertheless, the number of new infections worldwide continues to rise, particularly in women, and effective drug treatments have not yet reached the vast majority of infected individuals in resource-limited countries. The current status of antiretroviral therapy is therefore encouraging, but significant challenges remain. Although highly active antiretroviral therapy (HAART) provides durable control of virus replication in many patients, it is not devoid of unwanted secondary effects, some of which are now surfacing in aging populations under long-term treatment. The emergence of multidrug resistance and transmission of drug-resistant HIV strains limit the clinical efficacy of current therapy. Further simplification of treatment and identification of more effective drug combinations are needed to improve patient adherence, the most significant cause of treatment failure. Finding new drugs and novel drug targets may lead to redefining the goals of antiretroviral therapy, with an attempt to achieve the ultimate objective: the eradication of infection. Preclinical and clinical biomedical research, rational drug design and a close collaboration with regulatory agencies to set standards for the transition of new treatment concepts into the clinic will be the cornerstones of future progress. This special issue of Antiviral Research [85(1), 2010] highlights the principal milestones of antiretroviral research over 25 years of drug discovery and development and offers a comprehensive analysis by leading experts of the efforts being made to meet the challenges of effective control of HIV infection. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, vol. 85, issue 1, 2010.
机译:在发现叠氮胸苷(AZT)(一种临床上使用的第一种抗逆转录病毒药物)的治疗活性后的二十五年,人类免疫缺陷病毒(HIV)的感染至少在工业化世界中已成为可控制的慢性疾病,预期寿命和质量显着提高。尽管如此,全世界范围内的新感染人数仍在继续增加,特别是在妇女中,并且在资源有限的国家中,尚未达到有效的药物治疗,绝大多数感染者尚未得到治疗。因此,抗逆转录病毒疗法的现状令人鼓舞,但仍然存在重大挑战。尽管高活性抗逆转录病毒疗法(HAART)在许多患者中提供了对病毒复制的持久控制,但它并非没有不想要的继发作用,其中一些在长期治疗下的衰老人群中逐渐浮出水面。多药耐药性和耐药性HIV菌株的传播限制了当前疗法的临床疗效。需要进一步简化治疗并确定更有效的药物组合,以改善患者依从性,这是治疗失败的最重要原因。寻找新药和新药靶标可能会导致重新定义抗逆转录病毒疗法的目标,并试图实现最终目标:消除感染。临床前和临床生物医学研究,合理的药物设计以及与监管机构的密切合作,为新治疗概念向临床的过渡制定标准,将是未来进展的基石。这期抗病毒研究专刊[85(1),2010]重点介绍了25年药物发现和开发过程中抗逆转录病毒研究的主要里程碑,并提供了领先专家对为应对有效控制肝癌挑战而做出的努力的全面分析。 HIV感染。本文是《抗病毒研究》特刊的一部分,该刊物纪念抗逆转录病毒药物发现和开发25周年。 85,第1期,2010年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号